<DOC>
	<DOCNO>NCT01959945</DOCNO>
	<brief_summary>Flublok study previously child 6 -59 month age demonstrate less satisfactory immunogenicity result , especially 6-36 month age group . Thus , initial introduction Flublok Quadrivalent Formulation ( RIV4 ) pediatric population evaluate immunogenicity safety old child adolescent , age 6-17 . This clinical trial design demonstrate safety non-inferior immunogenicity Flublok-Q pediatric subject 6-17 year age compare IIV4 . Positive result study may support study young child .</brief_summary>
	<brief_title>Safety , Reactogenicity Immunogenicity Flublok Quadrivalent ( Recombinant Influenza Vaccine , Seasonal Formulation )</brief_title>
	<detailed_description>The U.S . Advisory Committee Immunization Practices ( ACIP ) recommend people ≥6 month age receive influenza vaccine annually . Recommendations influenza immunization child vary somewhat among country European Union , immunization child high risk complication influenza infection recommend WHO accord criterion country . Currently , immunization practice progress quadrivalent formulation inactivate influenza vaccine ( IIV4 ) approve US indicate population . Additionally , live attenuate vaccine ( LAIV4 ) approve U.S. individual age 2-49 year Flublok® ( RIV3 ) , purify trivalent recombinant hemagglutinin protein vaccine approve U.S. adult 18-49 year age . Children particular risk complication influenza , include B lineage , expansion Flublok indication pediatric age group quadrivalent formulation warrant .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>1 . Male female age 617 year ( Cohort A : 68 year age ; Cohort B : 917 year age ) 2 . Female subject childbearing potential ( defined onset menses ) must agree avoid become pregnant use effective method contraception practice abstinence least 28 day prior first study vaccine administration , completion study . Female subject childbearing potential must negative pregnancy test within 24 hour prior vaccine administration . 3 . In good general health , determine medical history target physical examination , indicate The parent ( ) legal representative ( ) potential subject must : 1 . Comprehend study requirement agree comply plan study procedures visit 2 . Provide write consent prior enrollment initiation study procedure Pediatric assent obtain accordance Institutional Review Board/Independent Ethics Committee determination . 1 . Known allergy egg , severe allergy ( e.g . anaphylaxis ) components either vaccine contraindication receipt comparator IIV4 2 . Immunosuppression result underlie illness treatment . Note : Subjects nasal topical steroid allow 3 . Active neoplastic disease history malignancy . 4 . History receive influenza vaccine within past 6 month plan study receive influenza vaccine outside study . 5 . History receive immunoglobulin blood product within 3 month prior enrollment study . 6 . Receipt nonstudy license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrollment study , plan study receive licensed vaccine within 4 week study dose [ See influenza vaccine ] . 7 . Acute chronic medical condition , opinion investigator , would render immunization unsafe would interfere evaluation immune responses 8 . History severe reaction follow immunization . 9 . An acute illness , include body temperature great 100*F , within 3 day prior immunization . 10 . Receipt experimental vaccine medication within 1 month prior enrollment study , expectation receive experimental vaccine , medication , blood product study Stage subject participate . 11 . Developmental delay , neurologic disorder , seizure disorder require ongoing medical management ( note : history seizure exclusion criterion ) . 12 . Any condition situation would , opinion investigator , place potential subject unacceptable risk injury render subject unable meet requirement protocol . 13 . History GuillainBarré syndrome . 14 . Known pregnancy , positive urine serum pregnancy test within 24 hour prior plan study vaccination , breastfeed . 15 . Concurrent participation another clinical trial ( active followup phase ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prevention</keyword>
</DOC>